Citadel Advisors
IPSC icon

Citadel Advisors’s Century Therapeutics IPSC Stock Holding History

Citadel Advisors’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$29.6K Buy
+13,100
New +$27.5K ﹤0.01% 12574
2025
Q3 		– Sell
-33,400
Closed -$18.7K – 13416
2025
Q2 		$18.7K Buy
33,400
+21,300
+176% +$11.4K ﹤0.01% 12119
2025
Q1 		$5.76K Buy
12,100
+2,400
+25% +$1.8K ﹤0.01% 13794
2024
Q4 		$9.8K Buy
9,700
+1,000
+11% +$1.36K ﹤0.01% 13626
2024
Q3 		$14.9K Buy
8,700
+1,700
+24% +$3.33K ﹤0.01% 13003
2024
Q2 		$17.9K Sell
7,000
-3,600
-34% -$11.4K ﹤0.01% 12740
2024
Q1 		$44.3K Buy
10,600
+7,300
+221% +$30.9K ﹤0.01% 12291
2023
Q4 		$11K Buy
3,300
+1,200
+57% +$2.19K ﹤0.01% 13069
2023
Q3 		$4.2K Buy
2,100
+700
+50% +$1.86K ﹤0.01% 13507
2023
Q2 		$4.42K Sell
1,400
-4,600
-77% -$14.8K ﹤0.01% 13597
2023
Q1 		$20.8K Sell
6,000
-53,900
-90% -$237K ﹤0.01% 13044
2022
Q4 		$307K Sell
59,900
-1,300
-2% -$12.3K ﹤0.01% 9266
2022
Q3 		$605K Buy
+61,200
New +$645K ﹤0.01% 8046

Other funds holding IPSC

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Citadel Advisors's IPSC Position: Q1 2026 in Review

Citadel Advisors sold out of Century Therapeutics (IPSC) in Q1 2026, closing a stake of 319,457 shares — an estimated $672K sold.

Citadel Advisors first reported a position in IPSC in Q3 2021 and held it in 16 quarters. The position peaked at $673K in Q4 2022. 72 funds tracked by Wall St. Rank hold IPSC as of Q1 2026.

  • Citadel Advisors reported no remaining Century Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 319,457 Century Therapeutics shares in Q1 2026, an estimated $672K.
  • Citadel Advisors first reported a position in Century Therapeutics in Q3 2021 and held it in 16 quarters.
  • Citadel Advisors's Century Therapeutics position peaked at $673K in Q4 2022.
  • 72 funds tracked by Wall St. Rank held Century Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.